Cargando…

Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

Significant progress has been achieved in human health in the European Union in recent years. New medicines, vaccines, and treatments have been developed to tackle some of the leading causes of disease and life-threatening illnesses. It is clear that investment in research and development (R&D)...

Descripción completa

Detalles Bibliográficos
Autores principales: Horgan, Denis, Spanic, Tanja, Apostolidis, Kathi, Curigliano, Giuseppe, Chorostowska-Wynimko, Joanna, Dauben, Hans-Peter, Lal, Jonathan A., Dziadziuszko, Rafal, Mayer-Nicolai, Christine, Kozaric, Marta, Jönsson, Bengt, Gutierrez-Ibarluzea, Iñaki, Fandel, Marie-Helene, Lopert, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408332/
https://www.ncbi.nlm.nih.gov/pubmed/36011250
http://dx.doi.org/10.3390/healthcare10081594
_version_ 1784774575355068416
author Horgan, Denis
Spanic, Tanja
Apostolidis, Kathi
Curigliano, Giuseppe
Chorostowska-Wynimko, Joanna
Dauben, Hans-Peter
Lal, Jonathan A.
Dziadziuszko, Rafal
Mayer-Nicolai, Christine
Kozaric, Marta
Jönsson, Bengt
Gutierrez-Ibarluzea, Iñaki
Fandel, Marie-Helene
Lopert, Ruth
author_facet Horgan, Denis
Spanic, Tanja
Apostolidis, Kathi
Curigliano, Giuseppe
Chorostowska-Wynimko, Joanna
Dauben, Hans-Peter
Lal, Jonathan A.
Dziadziuszko, Rafal
Mayer-Nicolai, Christine
Kozaric, Marta
Jönsson, Bengt
Gutierrez-Ibarluzea, Iñaki
Fandel, Marie-Helene
Lopert, Ruth
author_sort Horgan, Denis
collection PubMed
description Significant progress has been achieved in human health in the European Union in recent years. New medicines, vaccines, and treatments have been developed to tackle some of the leading causes of disease and life-threatening illnesses. It is clear that investment in research and development (R&D) for innovative medicines and treatments is essential for making progress in preventing and treating diseases. Ahead of the legislative process, which should begin by the end of 2022, discussions focus on how Europe can best promote the huge potential benefits of new science and technology within the regulatory framework. The challenges in European healthcare were spelled out by the panellists at the roundtable organised by European Alliance for Personalised Medicine (EAPM). Outcomes from panellists’ discussions have been summarized and re-arranged in this paper under five headings: innovation, unmet medical need, access, security of supply, adapting to progress, and efficiency. Some of the conclusions that emerged from the panel are a call for a better overall holistic vision of the future of pharmaceuticals and health in Europe and a collaborative effort among all stakeholders, seeing the delivery of medicines as part of a broader picture of healthcare.
format Online
Article
Text
id pubmed-9408332
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94083322022-08-26 Towards Better Pharmaceutical Provision in Europe—Who Decides the Future? Horgan, Denis Spanic, Tanja Apostolidis, Kathi Curigliano, Giuseppe Chorostowska-Wynimko, Joanna Dauben, Hans-Peter Lal, Jonathan A. Dziadziuszko, Rafal Mayer-Nicolai, Christine Kozaric, Marta Jönsson, Bengt Gutierrez-Ibarluzea, Iñaki Fandel, Marie-Helene Lopert, Ruth Healthcare (Basel) Perspective Significant progress has been achieved in human health in the European Union in recent years. New medicines, vaccines, and treatments have been developed to tackle some of the leading causes of disease and life-threatening illnesses. It is clear that investment in research and development (R&D) for innovative medicines and treatments is essential for making progress in preventing and treating diseases. Ahead of the legislative process, which should begin by the end of 2022, discussions focus on how Europe can best promote the huge potential benefits of new science and technology within the regulatory framework. The challenges in European healthcare were spelled out by the panellists at the roundtable organised by European Alliance for Personalised Medicine (EAPM). Outcomes from panellists’ discussions have been summarized and re-arranged in this paper under five headings: innovation, unmet medical need, access, security of supply, adapting to progress, and efficiency. Some of the conclusions that emerged from the panel are a call for a better overall holistic vision of the future of pharmaceuticals and health in Europe and a collaborative effort among all stakeholders, seeing the delivery of medicines as part of a broader picture of healthcare. MDPI 2022-08-22 /pmc/articles/PMC9408332/ /pubmed/36011250 http://dx.doi.org/10.3390/healthcare10081594 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Horgan, Denis
Spanic, Tanja
Apostolidis, Kathi
Curigliano, Giuseppe
Chorostowska-Wynimko, Joanna
Dauben, Hans-Peter
Lal, Jonathan A.
Dziadziuszko, Rafal
Mayer-Nicolai, Christine
Kozaric, Marta
Jönsson, Bengt
Gutierrez-Ibarluzea, Iñaki
Fandel, Marie-Helene
Lopert, Ruth
Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?
title Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?
title_full Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?
title_fullStr Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?
title_full_unstemmed Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?
title_short Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?
title_sort towards better pharmaceutical provision in europe—who decides the future?
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408332/
https://www.ncbi.nlm.nih.gov/pubmed/36011250
http://dx.doi.org/10.3390/healthcare10081594
work_keys_str_mv AT horgandenis towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT spanictanja towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT apostolidiskathi towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT curiglianogiuseppe towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT chorostowskawynimkojoanna towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT daubenhanspeter towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT laljonathana towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT dziadziuszkorafal towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT mayernicolaichristine towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT kozaricmarta towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT jonssonbengt towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT gutierrezibarluzeainaki towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT fandelmariehelene towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture
AT lopertruth towardsbetterpharmaceuticalprovisionineuropewhodecidesthefuture